Profile data is unavailable for this security.
About the company
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-22.38m
- Incorporated2020
- Employees13.00
- LocationNuvectis Pharma Inc1 Bridge Plaza, Suite 275FORT LEE 07024United StatesUSA
- Phone+1 (360) 837-7232
- Fax+1 (302) 636-5454
- Websitehttps://nuvectis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vor Biopharma Inc | 0.00 | -120.23m | 117.07m | 168.00 | -- | 0.9509 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Coya Therapeutics Inc | 6.13m | -10.30m | 118.55m | 8.00 | -- | 3.66 | -- | 19.34 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
Allakos Inc | 0.00 | -214.44m | 120.42m | 131.00 | -- | 1.15 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
FibroGen Inc | 167.49m | -240.46m | 122.35m | 486.00 | -- | -- | -- | 0.7305 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Nuvectis Pharma Inc | 0.00 | -22.38m | 122.43m | 13.00 | -- | 8.73 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Omega Therapeutics Inc | 4.94m | -92.28m | 123.00m | 93.00 | -- | 2.97 | -- | 24.90 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
PDS Biotechnology Corp | 0.00 | -43.89m | 123.98m | 25.00 | -- | 3.33 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 124.45m | 384.00 | -- | 0.3834 | -- | 0.3127 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
Regulus Therapeutics Inc | 0.00 | -31.37m | 125.69m | 28.00 | -- | 1.17 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
China Health Industries Holdings, Inc. | 117.28k | -1.51m | 125.84m | 32.00 | -- | -- | -- | 1,072.96 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
Tevogen Bio Holdings Inc | 0.00 | -67.33k | 127.53m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
Scpharmaceuticals Inc | 17.63m | -57.71m | 127.63m | 135.00 | -- | 5.20 | -- | 7.24 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
aTyr Pharma Inc | 588.00k | -53.93m | 128.36m | 56.00 | -- | 1.51 | -- | 218.30 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
FitLife Brands Inc | 58.51m | 7.30m | 128.75m | 37.00 | 18.93 | 4.38 | 17.37 | 2.20 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
Biostem Technologies Inc | 58.01m | 159.39k | 128.90m | 67.00 | -- | 19.56 | 335.71 | 2.22 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 338.68k | 1.91% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 284.92k | 1.60% |
Baldwin Brothers LLCas of 31 Mar 2024 | 154.13k | 0.87% |
Geode Capital Management LLCas of 31 Mar 2024 | 134.53k | 0.76% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 129.38k | 0.73% |
Renaissance Technologies LLCas of 31 Mar 2024 | 61.70k | 0.35% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 58.35k | 0.33% |
Marshall Wace LLPas of 31 Mar 2024 | 50.07k | 0.28% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 40.51k | 0.23% |
Millennium Management LLCas of 31 Mar 2024 | 39.50k | 0.22% |